ERBB2 and neoplasm: Many antibodies were used against various tumor antigens, such as TNT-3 [35,36] against universal nuclear antigen [45], BB4 [42] against CD138 (syndecan-1), 7D8 [38] against CD20, rG7S [39] against CD24, and antibodies against human epidermal growth factor receptor 2 (HER2) [37], prostate carcinoma membrane antigen (PSMA) [43] and carcinoembryonic antigen (CEA) [44].